Comparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis.

Kaplan–Meier analysis revealed a nominally significant lower risk of HF hospitalization with finerenone therapy at 1 year (HR 0.81; 95% CI: 0.66 to 0.99; log-rank p = 0.029), which was not robust after adjustment for multiple comparisons ( Table 2 and Figure 9 ).

also in 7,732 other papers

Although the point estimate favored finerenone, the result did not reach statistical significance and should be interpreted as a hypothesis-generating finding requiring further confirmation ( Table 2 and Figure 8 ).

also in 111,027 other papers